ODTC

Odonate Therapeutics

ODTC, USA

Odonate, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was formerly known as Odonate Therapeutics, Inc. and changed its name to Odonate, Inc. in March 2023. The company was founded in 2013 and is based in New York, New York.

https://www.odonate.com

Stock Price

$0.00

0%

increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
ODTC
stock
ODTC

DWC forks out P762M for subsidiaries Inquirer.net

Read more →
ODTC
stock
ODTC

Discovery World infusing P577 million fresh capital into units Philstar.com

Read more →

Showing 2 of 3

Finn Analysis

(Last Updated 2022-12-31)

Health Score

Price to Earnings Ratio (P/E)

-

Very High

7.29

Low ≥ 50

High ≤ 10

Price to Book Ratio (P/B)

-

Very Low

0.54

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

4.71 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Low

4.58 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Very High

0.03

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 0.00% of the total shares of Odonate Therapeutics

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2023-09-30

EPS Actual

0

EPS Estimate

0

EPS Difference

0

Surprise Percent

0%

Investing Fit Scorecard

(Last Updated 2022-12-31)

Deep Value
Strong Deep Value(8)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(5)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(1)
Momentum
Moderate Momentum(3.5)
Net Net
Possible Net-Net(3.5)
Quality
Moderate Quality(3.5)
Value
Undervalued(8.5)

Income Statement

(Last Updated 2022-12-31)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2022-12-31)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2022-12-31)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.